Skip to content

MDD(Mild Cognitive Impairment Delirium Dementia) Cohort

A Prospective, Longitudinal Cohort Study of the Incidence of Dementia After the Onset of Delirium in Patients With Mild Cognitive Impairment: MDD Cohort (Mild Cognitive Impairment Delirium Dementia)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05113446
Enrollment
163
Registered
2021-11-09
Start date
2021-07-01
Completion date
2025-12-31
Last updated
2022-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium, Dementia, Mild Cognitive Impairment

Keywords

delirium, mild cognitive impairment, dementia

Brief summary

* Identify the degree of delirium in subjects with mild cognitive impairment and find the risk factors of delirium. Mortality, hospital stay, and medical expenses are analyzed as clinical consequences related to delirium incidence. * Dementia conversion rate and conversion period of subjects with mild cognitive impairment with delirium and it identifies the effect of delirium on dementia conversion. * Develop an AI(Artificial intelligence) algorithm for predicting dementia transition in subjects with mild cognitive impairment based on the research results of the 1st, 2nd, and 3rd years.

Interventions

DIAGNOSTIC_TESTDelirium assessment using S-CAM

Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM

Sponsors

Keimyung University Dongsan Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 65 years of age or older who are admitted to a LTC * Patients diagnosed with mild cognitive impairment by doctors * Patients with a score of 18 or more and 23 or less on the Mini-Mental State Examination

Exclusion criteria

* Patients unable to measure the delirium assessment tool, The Short Confusion Assessment Methods (S-CAM) (Inouye, 2014) due to severe vision and hearing problems * Patients with serious psychiatric or neurological diagnosis,Patients who expire or were transferred on the day of admission - * Patients receiving emergency treatment at the time of the delirium assessment or unable to measure or intervene with S-CAM due to hospital circumstances

Design outcomes

Primary

MeasureTime frameDescription
Dementia conversion rate and transition period in participants with mild cognitive impairmentThe participant's dementia conversion is checked in units of 1 month, and the period until conversion to dementia is analyzed in units of 12 months for 36 months.descriptive statistics
Delirium incidence in participants with mild cognitive impairmentThe number of subjects evaluated as positive in the delirium assessment using S-CAM for 30 days from the 1st day of study participation is statistically calculated.descriptive statistics

Secondary

MeasureTime frameDescription
Risk factors affecting participants' deliriumOn the first day of data collection, the characteristics of subjects are collected through medical records. After 12 months, the risk factors affecting the occurrence of delirium among the characteristics of the subject are analyzed.Logistic Regression
MortalityIt is statistically calculated in 30-day, 60-day, 12-month, 24-month, and 36-month increments.Kaplan-Meier survival, Cox proportional hazard regression, Logistic Regression
hospital length of stayThe period from hospitalization to discharge is calculated in days and analyzed in units of 12 months.Linear Regression
healthcare costsFrom the healthcare costs consumed during the hospital length of stay, the direct healthcare costs used only for treatment are calculated in won units and analyzed in units of 12 months.Linear Regression

Countries

South Korea

Contacts

Primary ContactKyoung ja Moon, doctor
kjmoon2150@gmail.com+821023026302
Backup Contactmin a Park
kjmoon2150@gmail.com+821023026302

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026